BioStock: Aptahem’s wish list for next year’s Christmas

Aptahem, which is developing an emergency medicine for the treatment of sepsis, carried out an oversubscribed rights issue in October. During the next year, redemption of two warrants await,s and the company is full swing to complete the final development steps in the preclinical program before reaching the clinic. CEO Mikael Lindstam share his view about this task and other activities next year, before the phase I study can begin.

Read the full interview with Mikael Lindstam at biostock.se:

https://www.biostock.se/en/aptahems-wish-list-for-next-years-christmas/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se